30S Stock Chart & Stats
€1.93
>-€0.01(-0.49%)
At close: 4:00 PM EST
€1.93
>-€0.01(-0.49%)
Day’s Range― - ―
52-Week Range€0.93 - €2.58
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€130.65M
Enterprise Value€1.32K
Total Cash (Recent Filing)€486.31M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)7.6
Beta0.58
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.34
Shares Outstanding138,030,140
10 Day Avg. Volume50
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€24.00M
Bulls Say, Bears Say
Bulls Say
Strong Current ProfitabilityThe sharp move from heavy losses in 2021–2023 to strong profitability in 2025 and the latest TTM improves internal funding capacity and supports continued development. If maintained, higher margins can provide resilience while Saniona advances its pipeline and pursues partnerships.
Debt-free Balance SheetA debt-free structure and substantial equity base reduce financing pressure and interest obligations, giving Saniona more flexibility to fund research and manage development timelines. This is a meaningful improvement from prior leverage and negative equity, strengthening financial resilience over the next several quarters.
Positive Free Cash FlowPositive operating and free cash flow across the latest annual and trailing periods indicates that the business has recently generated cash rather than relying entirely on external funding. That supports ongoing operations and gives management greater flexibility in allocating capital to development programs.
Bears Say
Highly Volatile Revenue BaseThe sharp reversal in revenue performance makes current earnings less predictable and raises questions about how much profitability reflects recurring operations versus milestone or licensing income. Such volatility can complicate planning, reduce visibility into future funding capacity, and weaken confidence in sustained growth.
Incomplete Cash ConversionFree cash flow below net income indicates that reported earnings are not converting fully into cash, while uneven annual FCF makes the improvement less consistent. This can limit the reliability of internally generated funding and increase dependence on successful partnerships or future capital raises.
Recent Capital Structure InstabilityAlthough the balance sheet is currently conservative, the recent history of leverage and negative equity shows that Saniona’s capital structure has been unstable. That history signals vulnerability if profitability or cash generation weakens, particularly given the financing needs of a development-stage biotechnology pipeline.
Saniona AB News
30S FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was €0.93 and its highest was €2.58 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is €130.65M.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Nov 26, 2026 which is in 74 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on Aug 27, 2026. The company reported -€0.038 earnings per share for the quarter.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -€0.038 in its last earnings report. Following the earnings report the stock price went down -0.672%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in DE:30S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Technical Analysis
Hansa Biopharma AB
―
Medivir AB
―
Camurus AB
―
AlzeCure Pharma AB
―
BioArctic AB Class B
―